Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Continuous glucose monitoring in the management of patients after gastric bypass

Flores MR, Soto RCC, Velázquez VV, Cortés RRS, Salinas CA, García EG.

Endocrinol Diabetes Metab Case Rep. 2019 Jul 26;2019(1):1-6. doi: 10.1530/EDM-18-0155.

2.

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis.

Taylor PC, Weinblatt ME, Burmester GR, Rooney TP, Witt S, Walls CD, Issa M, Salinas CA, Saifan C, Zhang X, Cardoso A, González-Gay MA, Takeuchi T.

Arthritis Rheumatol. 2019 Jul;71(7):1042-1055. doi: 10.1002/art.40841. Epub 2019 May 25.

3.

MRGPR-mediated activation of local mast cells clears cutaneous bacterial infection and protects against reinfection.

Arifuzzaman M, Mobley YR, Choi HW, Bist P, Salinas CA, Brown ZD, Chen SL, Staats HF, Abraham SN.

Sci Adv. 2019 Jan 2;5(1):eaav0216. doi: 10.1126/sciadv.aav0216. eCollection 2019 Jan.

4.

Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with 18F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles.

Lohith TG, Bennacef I, Vandenberghe R, Vandenbulcke M, Salinas CA, Declercq R, Reynders T, Telan-Choing NF, Riffel K, Celen S, Serdons K, Bormans G, Tsai K, Walji A, Hostetler ED, Evelhoch JL, Van Laere K, Forman M, Stoch A, Sur C, Struyk A.

J Nucl Med. 2019 Jan;60(1):107-114. doi: 10.2967/jnumed.118.208215. Epub 2018 Jun 7.

PMID:
29880509
5.

Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection.

Price AM, Dai J, Bazot Q, Patel L, Nikitin PA, Djavadian R, Winter PS, Salinas CA, Barry AP, Wood KC, Johannsen EC, Letai A, Allday MJ, Luftig MA.

Elife. 2017 Apr 20;6. pii: e22509. doi: 10.7554/eLife.22509.

6.

The simplified reference tissue model: model assumption violations and their impact on binding potential.

Salinas CA, Searle GE, Gunn RN.

J Cereb Blood Flow Metab. 2015 Feb;35(2):304-11. doi: 10.1038/jcbfm.2014.202. Epub 2014 Nov 26.

7.

Prostate cancer in young men: an important clinical entity.

Salinas CA, Tsodikov A, Ishak-Howard M, Cooney KA.

Nat Rev Urol. 2014 Jun;11(6):317-23. doi: 10.1038/nrurol.2014.91. Epub 2014 May 13. Review.

8.

Spatio-temporal pharmacokinetic model based registration of 4D PET neuroimaging data.

Jiao J, Searle GE, Tziortzi AC, Salinas CA, Gunn RN, Schnabel JA.

Neuroimage. 2014 Jan 1;84:225-35. doi: 10.1016/j.neuroimage.2013.08.031. Epub 2013 Aug 28.

PMID:
23994455
9.

Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography.

Comley RA, Salinas CA, Slifstein M, Petrone M, Marzano C, Bennacef I, Shotbolt P, Van der Aart J, Neve M, Iavarone L, Gomeni R, Laruelle M, Gray FA, Gunn RN, Rabiner EA.

J Pharmacol Exp Ther. 2013 Aug;346(2):311-7. doi: 10.1124/jpet.112.202895. Epub 2013 May 17.

PMID:
23685546
10.

Imaging imidazoline-I2 binding sites in porcine brain using 11C-BU99008.

Kealey S, Turner EM, Husbands SM, Salinas CA, Jakobsen S, Tyacke RJ, Nutt DJ, Parker CA, Gee AD.

J Nucl Med. 2013 Jan;54(1):139-44. doi: 10.2967/jnumed.112.108258. Epub 2012 Dec 5.

11.

Identification of a novel NBN truncating mutation in a family with hereditary prostate cancer.

Zuhlke KA, Johnson AM, Okoth LA, Stoffel EM, Robbins CM, Tembe WA, Salinas CA, Zheng SL, Xu J, Carpten JD, Lange EM, Isaacs WB, Cooney KA.

Fam Cancer. 2012 Dec;11(4):595-600. doi: 10.1007/s10689-012-9555-1.

12.

Combining PET biodistribution and equilibrium dialysis assays to assess the free brain concentration and BBB transport of CNS drugs.

Gunn RN, Summerfield SG, Salinas CA, Read KD, Guo Q, Searle GE, Parker CA, Jeffrey P, Laruelle M.

J Cereb Blood Flow Metab. 2012 May;32(5):874-83. doi: 10.1038/jcbfm.2012.1. Epub 2012 Jan 25.

13.

Advances in biomathematical modeling for PET neuroreceptor imaging.

Gunn RN, Guo Q, Salinas CA, Tziortzi AC, Searle GE.

Drug Discov Today Technol. 2011 Summer;8(2-4):e45-51. doi: 10.1016/j.ddtec.2012.01.001.

PMID:
24990262
14.

Early onset prostate cancer has a significant genetic component.

Lange EM, Salinas CA, Zuhlke KA, Ray AM, Wang Y, Lu Y, Ho LA, Luo J, Cooney KA.

Prostate. 2012 Feb 1;72(2):147-56. doi: 10.1002/pros.21414. Epub 2011 May 2.

15.

Genetic polymorphisms in inflammation pathway genes and prostate cancer risk.

Kwon EM, Salinas CA, Kolb S, Fu R, Feng Z, Stanford JL, Ostrander EA.

Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):923-33. doi: 10.1158/1055-9965.EPI-10-0994. Epub 2011 Mar 23.

16.

Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy.

Abanades S, van der Aart J, Barletta JA, Marzano C, Searle GE, Salinas CA, Ahmad JJ, Reiley RR, Pampols-Maso S, Zamuner S, Cunningham VJ, Rabiner EA, Laruelle MA, Gunn RN.

J Cereb Blood Flow Metab. 2011 Mar;31(3):944-52. doi: 10.1038/jcbfm.2010.175. Epub 2010 Oct 13.

17.

Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk.

Salinas CA, Kwon EM, FitzGerald LM, Feng Z, Nelson PS, Ostrander EA, Peters U, Stanford JL.

Am J Epidemiol. 2010 Sep 1;172(5):578-90. doi: 10.1093/aje/kwq175. Epub 2010 Aug 5.

18.

11C-GSK189254: a selective radioligand for in vivo central nervous system imaging of histamine H3 receptors by PET.

Plisson C, Gunn RN, Cunningham VJ, Bender D, Salinas CA, Medhurst AD, Roberts JC, Laruelle M, Gee AD.

J Nucl Med. 2009 Dec;50(12):2064-72. doi: 10.2967/jnumed.109.062919. Epub 2009 Nov 12.

19.

Genetic variation in DNA repair genes and prostate cancer risk: results from a population-based study.

Agalliu I, Kwon EM, Salinas CA, Koopmeiners JS, Ostrander EA, Stanford JL.

Cancer Causes Control. 2010 Feb;21(2):289-300. doi: 10.1007/s10552-009-9461-5. Epub 2009 Nov 10.

20.

Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort.

Wright JL, Salinas CA, Lin DW, Kolb S, Koopmeiners J, Feng Z, Stanford JL.

J Urol. 2009 Dec;182(6):2702-7. doi: 10.1016/j.juro.2009.08.026.

21.

Dopamine D3 receptor antagonists: the quest for a potentially selective PET ligand. Part 3: Radiosynthesis and in vivo studies.

Bennacef I, Salinas CA, Bonasera TA, Gunn RN, Audrain H, Jakobsen S, Nabulsi N, Weinzimmer D, Carson RE, Huang Y, Holmes I, Micheli F, Heidbreder C, Gentile G, Rossi T, Laruelle M.

Bioorg Med Chem Lett. 2009 Sep 1;19(17):5056-9. doi: 10.1016/j.bmcl.2009.07.055. Epub 2009 Jul 25.

PMID:
19635669
22.

Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features.

Fitzgerald LM, Kwon EM, Koopmeiners JS, Salinas CA, Stanford JL, Ostrander EA.

Clin Cancer Res. 2009 May 1;15(9):3231-7. doi: 10.1158/1078-0432.CCR-08-2190. Epub 2009 Apr 14.

23.

Evaluation of 8q24 and 17q risk loci and prostate cancer mortality.

Penney KL, Salinas CA, Pomerantz M, Schumacher FR, Beckwith CA, Lee GS, Oh WK, Sartor O, Ostrander EA, Kurth T, Ma J, Mucci L, Stanford JL, Kantoff PW, Hunter DJ, Stampfer MJ, Freedman ML.

Clin Cancer Res. 2009 May 1;15(9):3223-30. doi: 10.1158/1078-0432.CCR-08-2733. Epub 2009 Apr 14.

24.

Clinical utility of five genetic variants for predicting prostate cancer risk and mortality.

Salinas CA, Koopmeiners JS, Kwon EM, FitzGerald L, Lin DW, Ostrander EA, Feng Z, Stanford JL.

Prostate. 2009 Mar 1;69(4):363-72. doi: 10.1002/pros.20887.

25.

Vasectomy and the risk of prostate cancer.

Holt SK, Salinas CA, Stanford JL.

J Urol. 2008 Dec;180(6):2565-7; discussion 2567-8. doi: 10.1016/j.juro.2008.08.042. Epub 2008 Oct 19.

26.

Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium.

Kote-Jarai Z, Easton DF, Stanford JL, Ostrander EA, Schleutker J, Ingles SA, Schaid D, Thibodeau S, Dörk T, Neal D, Donovan J, Hamdy F, Cox A, Maier C, Vogel W, Guy M, Muir K, Lophatananon A, Kedda MA, Spurdle A, Steginga S, John EM, Giles G, Hopper J, Chappuis PO, Hutter P, Foulkes WD, Hamel N, Salinas CA, Koopmeiners JS, Karyadi DM, Johanneson B, Wahlfors T, Tammela TL, Stern MC, Corral R, McDonnell SK, Schürmann P, Meyer A, Kuefer R, Leongamornlert DA, Tymrakiewicz M, Liu JF, O'Mara T, Gardiner RA, Aitken J, Joshi AD, Severi G, English DR, Southey M, Edwards SM, Al Olama AA; PRACTICAL Consortium, Eeles RA.

Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2052-61. doi: 10.1158/1055-9965.EPI-08-0317. Erratum in: Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2901. Donovan, Jenny [added]; Hamdy, Freddie [added].

27.

Statin use and risk of prostate cancer: results from a population-based epidemiologic study.

Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL.

Am J Epidemiol. 2008 Aug 1;168(3):250-60. doi: 10.1093/aje/kwn141. Epub 2008 Jun 12.

28.

Epiphytic dinoflagellates associated with ciguatera in the northwestern coast of Cuba.

Delgado G, Lechuga-Devéze CH, Popowski G, Troccoli L, Salinas CA.

Rev Biol Trop. 2006 Jun;54(2):299-310.

PMID:
18494300
29.

Multiple independent genetic variants in the 8q24 region are associated with prostate cancer risk.

Salinas CA, Kwon E, Carlson CS, Koopmeiners JS, Feng Z, Karyadi DM, Ostrander EA, Stanford JL.

Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1203-13. doi: 10.1158/1055-9965.EPI-07-2811.

30.

Genetic design of biologically inspired receptive fields for neural pattern recognition.

Perez CA, Salinas CA, Estevez PA, Valenzuela PM.

IEEE Trans Syst Man Cybern B Cybern. 2003;33(2):258-70. doi: 10.1109/TSMCB.2003.810441.

PMID:
18238176
31.

The ATP-binding cassette transporter subfamily A member 1 (ABC-A1) and type 2 diabetes: an association beyond HDL cholesterol.

Salinas CA, Cruz-Bautista I, Mehta R, Villarreal-Molina MT, Pérez FJ, Tusié-Luna MT, Canizales-Quinteros S.

Curr Diabetes Rev. 2007 Nov;3(4):264-7. Review.

PMID:
18220685
32.

Validity of model approximations for receptor-ligand kinetics in nuclear medicine.

Salinas CA, Muzic RF Jr, Saidel GM.

Med Phys. 2007 May;34(5):1693-703.

PMID:
17555251
33.

Polymorphisms in the glutathione S-transferase M1, T1, and P1 genes and prostate cancer prognosis.

Agalliu I, Lin DW, Salinas CA, Feng Z, Stanford JL.

Prostate. 2006 Oct 1;66(14):1535-41.

PMID:
16921513
34.

Statins and the risk of cancer.

Salinas CA, Agalliu I, Stanford JL, Lin DW.

JAMA. 2006 Jun 21;295(23):2721; author reply 2721-2. No abstract available.

PMID:
16788124
35.

Glutathione S-transferase M1, T1, and P1 polymorphisms and prostate cancer risk in middle-aged men.

Agalliu I, Langeberg WJ, Lampe JW, Salinas CA, Stanford JL.

Prostate. 2006 Feb 1;66(2):146-56.

PMID:
16173036
36.

Polymorphisms in the androgen receptor and the prostate-specific antigen genes and prostate cancer risk.

Salinas CA, Austin MA, Ostrander EO, Stanford JL.

Prostate. 2005 Sep 15;65(1):58-65.

PMID:
15810021
37.

Psychosocial factors associated with poor diabetes self-care management in a specialized center in Mexico City.

Lerman I, Lozano L, Villa AR, Hernández-Jiménez S, Weinger K, Caballero AE, Salinas CA, Velasco ML, Gómez-Pérez FJ, Rull JA.

Biomed Pharmacother. 2004 Dec;58(10):566-70.

PMID:
15589064
38.

Alcohol consumption and risk of prostate cancer in middle-aged men.

Schoonen WM, Salinas CA, Kiemeney LA, Stanford JL.

Int J Cancer. 2005 Jan 1;113(1):133-40.

39.

Characterization of a Drosophila homologue of the 160-kDa subunit of the cleavage and polyadenylation specificity factor CPSF.

Salinas CA, Sinclair DA, O'Hare K, Brock HW.

Mol Gen Genet. 1998 Apr;257(6):672-80.

PMID:
9604891
40.

The Additional sex combs gene of Drosophila encodes a chromatin protein that binds to shared and unique Polycomb group sites on polytene chromosomes.

Sinclair DA, Milne TA, Hodgson JW, Shellard J, Salinas CA, Kyba M, Randazzo F, Brock HW.

Development. 1998 Apr;125(7):1207-16.

Supplemental Content

Loading ...
Support Center